| Ytd | -73.57% | |
| 1y | -93.10% |
| Open | 2.80 | Prev Close | 2.91 | Low | 2.62 | High | 3.14 | Mkt Cap | 2.24M |
| Vol | 30.28K | Avg Vol | 435.21K | EPS | -3.30 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.44 | Short Ratio | 0.17 | Inst. Own | 35.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.32 | 200-d Avg | 14.26 | 1yr Est | 196.13 |
BDRX News
June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meet
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Priv
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&
U.S. stock futures lower on Thursday with Applied Digital Corp. (APLD) falling sharply in pre-market
GAME stock rose 52.3% in pre-market trading after reporting positive EBITDA and financials. Other ga
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from
Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said
Biodexa Announces Partnership with SyngeneTo Manufacture MTX240 GMP Clinical Trial SuppliesBiodexa P
Biodexa Launches Global Early Access Program for eRapa for FAP PatientsThrough Strategic Partnership
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a p
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a p
Biodexa Announces Pricing of $10 Million Public OfferingBiodexa Pharmaceuticals PLC, (NASDAQ:BDRX) (
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is n
Biodexa's stock dipped 3.67% to $10.50 in after-hours trading following a strong gain during the